Burcu Azak Pazarlar

Burcu Azak Pazarlar

Auto-generated profile, based on publicly available information

Burcu Azak Pazarlar

Neurobiology Research Unit, University Hospital Rigshospitalet, Copenhagen, Denmark; Institute of Neuroscience, University of Copenhagen, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2022 in Molecular Brain
Verified
Journal Article
Open access
PDF file
BPBurcu A. Pazarlar
Burcu A. Pazarlar
SASanjay S. Aripaka
Sanjay S. Aripaka
VPViktor Petukhov
Viktor Petukhov
LPLars Pinborg
Lars Pinborg
KKKonstantin Khodosevich
Konstantin Khodosevich
JMJens D. Mikkelsen
Jens D. Mikkelsen
Synaptic vesicle glycoprotein-2 (SV2) is a family of proteins consisting of SV2A, SV2B, and SV2C. This protein family has attracted attention in recent years after SV2A was shown to be an epileptic drug target and a perhaps a biomarker of synaptic density. So far, the anatomical localization of these proteins in the rodent and human brain have been reported, but co-expression of SV2 genes on a cellular level, their expressions in the human brain, comparison to radioligand binding, any possible regulation in epilepsy are not known. We have here analyzed the expression of SV2 genes in neuronal subtypes in the temporal neocortex in selected specimens by using single nucleus-RNA sequencing, and performed quantitative PCR in populations of temporal lobe epilepsy (TLE) patients and healthy controls. [3H]-UCB-J autoradiography was performed to analyze the correlation between the mRNA transcript and binding capacity to SV2A. Our data showed that the SV2A transcript is expressed in all glutamatergic and GABAergic cortical subtypes, while SV2B expression is restricted to only the glutamatergic neurons and SV2C has very limited expression in a small subgroup of GABAergic interneurons. The level of [3H]-UCB-J binding and the concentration of SV2A mRNA is strongly correlated in each patient, and the expression is lower in the TLE patients. There is no relationship between SV2A expression and age, sex, seizure frequency, duration of epilepsy, or whether patients were recently treated with levetiracetam or not. Collectively, these findings point out a neuronal subtype-specific distribution of the expression of the three SV2 genes, and the lower levels of both radioligand binding and expression further emphasize the significance of these proteins in this disease.

3 May 2025 in Synapse
Verified
Journal Article
Open access
BPBurcu Azak Pazarlar
Burcu Azak Pazarlar
CECansu Bilister Egilmez
Cansu Bilister Egilmez
EOEser Öz Oyar
Eser Öz Oyar
JMJens D. Mikkelsen
Jens D. Mikkelsen
Aim/hypothesis: Diabetes mellitus has been reported to be a risk factor for cognitive dysfunction, depression, stroke, and seizures. Diabetic pathology is believed to interfere with synaptic plasticity. Synaptic vesicle glycoprotein 2A (SV2A) is a presynaptic vesicular protein and a popular synaptic density imaging marker. We investigated the effect of chronic hyperglycemia on the expression of SV2A in the cerebral cortex and hippocampus of rats and compared it to other presynaptic markers, such as GAP43, Synaptotagmin‐1, and SNAP25.Methods: A single dose of streptozotocin (STZ, 45 mg/kg, i.p.) was administered to adult male rats, resulting in sustained hyperglycemia and reduced plasma insulin levels. Controls were injected with saline, and another STZ group was treated with insulin. Fasting blood glucose (FBG) and fasting plasma insulin (FPI) levels were monitored throughout the observation period, and the level of SV2A was determined by radioligand, [3H]UCB‐J, binding capacity using in‐vitro autoradiography and by ELISA. Similarly, the tissue concentration of other synaptic proteins GAP43, SNAP25, and SYN1 was measured using ELISA. Quantitative RT‐qPCR was performed to measure Sv2a, Sv2b, and Sv2c transcripts. Finally, hippocampal and cortical glutamate levels were measured in all tissues.Results: [3H]UCB‐J binding, SV2A (pg/mg protein) and Sv2a mRNA levels were significantly higher in hyperglycemic rats. The SV2A concentration detected by ELISA and [3H]UCB‐J binding showed, as expected, a positive correlation with each other. The same positive and significant correlation was seen between SV2A, FBG, and glutamate l levels across animals (p ≤ 0.001). Notably, there was no difference and no linearity between FBG and other presynaptic markers such as GAP43, Synaptotagmin‐1, and SNAP25.Conclusions: Unlike other synaptic markers (e.g., SNAP25, SYN‐1), SV2A levels rise independently of synaptic density, correlating with elevated glutamate and metabolic activity. These findings raise doubt about SV2A's role as a pure synaptic density marker.

18 August 2025 in Neuroscience
Verified
Journal Article
Open access
SASanjay S. Aripaka
Sanjay S. Aripaka
BPBurcu A. Pazarlar
Burcu A. Pazarlar
LPLars H. Pinborg
Lars H. Pinborg
KLKaren B. Larsen
Karen B. Larsen
FGFrancois Gastambide
Francois Gastambide
JMJens Mikkelsen
Jens Mikkelsen
Monoacylglycerol lipase (MAGL) inhibitors are considered as drug candidates for epilepsy. In order to determine the level of MAGL and evaluate changes in the epileptic brain, we have validated and used autoradiography and the MAGL radiotracer [3H]T-401 on resected temporal neocortex specimens obtained from patients with temporal lobe epilepsy and in brains from mice with chronic reoccurring hippocampal seizures. Saturation experiments revealed a KD around 4 nM for the human temporal cortex and 7 nM for the mouse brain. In the human brain, binding of [3H]T-401 was detected mostly in the grey matter, and in the subcortical white matter in lower amounts. The levels were strongly correlated in the two cortical compartments. The level of [3H]T-401 binding in the human temporal cortex varied about a 4-fold among the patients, but was not correlated to either epilepsy duration or the age of the patients. In the epileptic mouse brain, a significant reduction was observed bilaterally in the hippocampus, as well as in other cortical regions, including the temporal cortex. Interestingly, a highly significant negative correlation was seen between MAGL and binding of [3H]PBR28 to the translocator protein 18 kDa (TSPO) expressed in glia. These data support the presence of MAGL in neuronal and non-neuronal cells, and indicate that MAGL levels in the brains of either patients with epilepsy or mice after intra-hippocampal kainic acid injection are reduced not only in the epileptic zone in the hippocampus, but more widespread in the brain.

10 October 2025 in Epilepsy & Behavior
Verified
Journal Article
Open access
AAAje Al-Awssi
Aje Al-Awssi
BPBurcu A. Pazarlar
Burcu A. Pazarlar
LPLars H. Pinborg
Lars H. Pinborg
JMJens Mikkelsen
Jens Mikkelsen
Cognitive impairments are commonly observed in individuals with mesial temporal lobe epilepsy (mTLE), yet the underlying mechanisms remain poorly elucidated. This study investigates the potential relationship between neuroinflammation as determined using radioligand binding to markers of neuroinflammation and cognitive dysfunction in this patient population. Quantitative autoradiography was performed using the radioligands [123I]CLINDE (for 18 kDa translocator protein (TSPO)) and [3H]JNJ-64413739 (for P2X purinoceptor 7 receptor (P2X7R)) on temporal neocortical specimens removed neurosurgically from 17 patients with drug-resistant mTLE (41.2 % male; mean age = 41.2 ± 11.4 years). Preoperative cognitive function was assessed using the Wechsler Adult Intelligence Scale, Fourth Edition (WAIS-IV), and Pearson's correlation analyses were conducted to examine associations between radioligand binding and cognitive scores, with subgroup analyses based on the laterality of the epileptic focus. Multiple regression analyses were employed to control for potential confounders, including seizure frequency, epilepsy duration, and lateralization. Significant associations emerged exclusively in patients with left temporal lobe epilepsy. In this subgroup, [123I]CLINDE binding showed a positive correlation with the Verbal Comprehension Index (VCI) (p = 0.037) and the Processing Speed Index (PSI) (p = 0.011). Additionally, [3H]JNJ-64413739 binding was significantly correlated with the Working Memory Index (WMI) (p = 0.029). Sensitivity analyses confirmed a robust association between [123I]CLINDE binding and VCI score (p = 0.002, β = 0.19). These findings demonstrate a positive correlation between TSPO expression and cognitive function in patients with drug-resistant mTLE, and the results contribute to a growing body of evidence linking neuroinflammatory processes to cognitive outcomes in epilepsy.